The lock up and fixed increase plan for subscription by actual controllers and the draft incentive plan for restricted shares in 2022 were launched at the same time, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) it was clear that it would further return to its main business and focus on the development of innovative traditional Chinese medicine.
On March 6, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) released the plan for non-public offering of shares in 2022, saying that it is planned to raise no more than 270 million yuan at the issue price of 4.74 yuan / share. After deducting the issuance expenses, all the raised funds will be used to supplement working capital and repay bank loans.
It is worth noting that this time, the new yuan industrial investment controlled by Hunan Fangsheng Pharmaceutical Co.Ltd(603998) actual controller Zhang Qinghua will take the subscription and fixed increase. By then, Zhang Qinghua’s proportion of control in Hunan Fangsheng Pharmaceutical Co.Ltd(603998) will increase from 39.69% to 46.76%.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) said that after the issuance, the proportion of the control right of the actual controller further increased, which helped to stabilize the control right of the company and improve the decision-making efficiency of the company. At the same time, Xinyuan Industrial Investment controlled by Zhang Qinghua subscribed for fixed increase in cash, which shows the actual controller’s support for the development of listed companies and confidence in the future prospects of the company, and helps to enhance investors’ expectations for the future development of the company.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) also said that the company is committed to building a health industry group with innovative traditional Chinese medicine as the core, and driving the continuous improvement of the company’s core competitiveness with the two wheels of “innovative traditional Chinese medicine R & D” and “management reform”. After years of development and precipitation, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) has formed a product group consisting of Chinese patent medicine for skeletal muscle system diseases, cardiovascular and cerebrovascular diseases, women and children, respiratory system, chemical medicine, cardiovascular system and anti infection drugs.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) has profound accumulation in the field of traditional Chinese medicine. From 2017 to January 2022, the State Food and Drug Administration approved a total of 21 traditional Chinese medicines, and Hunan Fangsheng Pharmaceutical Co.Ltd(603998) independently developed Xiaoer Jingxing Zhike granules (category 6.1 traditional Chinese Medicine) and Xuanqi Jiangu tablets (category 1.1 traditional Chinese Medicine) were approved in 2019 and 2021 respectively.
On March 6, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) synchronously launched the 2022 restricted stock incentive plan (Draft), with a total of 15 million restricted shares to be granted, accounting for about 3.49% of the total share capital of the current company; The total number of incentive objects granted for the first time is 270, and the grant price is 3.15 yuan / share.
According to the draft, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) company level performance assessment requirements: Based on 2021, the growth rate of operating revenue in 2022 shall not be less than 10% or the growth rate of net profit in 2022 shall not be less than 12%; Based on 2021, the growth rate of operating revenue in 2023 shall not be less than 15% or the growth rate of net profit in 2023 shall not be less than 17%.
